web analytics
5.7 C
Munich
Monday, October 18, 2021

Major Runner RXMD (Progressive Care) Surging on Record Revenues, Up Listing & Aggressive Expansion of its COVID-19 Testing Service

RXMD (Progressive Care) has been making a major move up the charts in recent months from lows well under $0.03 to recent highs of $0.195. RXMD has been under heavy accumulation recently and volume has picked up substantially since a slow December with RXMD regularly trading several million USD per day in dollar volume as a new era of penny stock speculators fueled by robinhood and its 100 million new trading accounts take on the bulletin boards. These are different times than just a few short years ago; now penny stocks such as TSNP can achieve a $6 billion plus market valuation and trade $375 million in dollar volume in a day on the bulletin boards. And TSNP has no stronger fundamentals than RXMD does. Microcapdaily has reported on RXMD incredible rise over the years from Pink Sheets with the yield designation to fully reporting OTCQB with plans to up list to a major exchange. The stock has runner in its blood and a history of big moves, skyrocketing from well under a penny to highs of $0.27 in early 2018. When a penny stock such as RXMD heats up, penny stock speculators pay attention.” 

RXMD just reported a record year in 2020 with more than 530,000 prescriptions filed, the highest in Company history. RXMD did over $40.6 million in sales, the highest in Company history. 340B revenue was $2.8 million, representing year-over-year growth of 323% compared to the year ended December 31, 2019. Recently RXMD has launched an aggressive expansion of its COVID-19 testing service registered through the FDA under its Emergency Use Authorization (“EUA”) guidelines, featuring Polymerase Chain Reaction (“PCR”) and Antigen testing systems that produces rapid detection of the SARS-CoV-2 virus with market-leading accuracy in 15 to 45 minutes. To date, the Company has successfully tested over 5,000 patients and built a reputation as a preferred provider for in-patient and out-patient COVID-19 Rapid Testing solution at its Pharmacy locations in North Miami Beach, Palm Springs and Orlando pharmacies.  

Progressive Care Inc. (OTCQB: RXMD), through its subsidiaries, is a Florida health services organization and provider of prescription pharmaceuticals, compounded medications, provider of tele-pharmacy services, the sale of anti-retroviral medications, medication therapy management (MTM), the supply of prescription medications to long-term care facilities, and health practice risk management. The Company boasts 4 physical pharmacy locations (in North Miami Beach, Davie, Palm Springs, and Orlando) with 5-star performance ratings and nearly 125 employees from which to launch further expansion and sales growth. Progressive Care has been featured by mainstream press including in prestigious online magazines such as Forbes, Microcapdaily, and HuffPost. PharmCo Rx is licensed in Colorado, Connecticut, Florida, Georgia, Illinois, Nevada, New Jersey, New York, Pennsylvania, Texas, Utah, Arizona, Massachusetts and Minnesota. 

For years Microcapdaily has reported on RXMD starting on January 8, 2015 stating: RXMD is a fascinating story taking the bb’s by storm. The stock which has been locked in a battle between $0.001 lows and $0.01 highs has exploded out of its trading range well into penny land. While RXMD still remains quite unknown the stock is quickly gaining the attention of a growing shareholder base who swears this one goes much higher. Everyone knows just how explosive these OTC pharmacy plays can be.” More recently on July 29, 2020 Microcapdaily reported on RXMD: “RXMD is moving steadily higher in recent trading on growing volume as the Company reports record operating results and expands its covid-19 antibody testing operations. Microcapdaily has reported on RXMD incredible rise over the years from Pink Sheets with the yield designation to fully reporting OTCQB with plans to up list to a major exchange. The stock has runner in its blood and a history of big moves, skyrocketing from well under a penny to highs of $0.27 in early 2018. When a penny stock such as RXMD heats up, penny stock speculators pay attention.” 

Has Progressive Care Inc. (OTCMKTS:RXMD) Turned an Important ...

To Find out the inside Scoop on RXMD Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

RXMD

RXMD has emerged as a revenue powerhouse in recent years recently reporting record 2020 revenues topped $40 million up over 75% from last year. In a recent update management stated: RXMD had a record year in 2020: “We filled more than 530,000 prescriptions in 2020, the highest in Company history. We had over $40.6 million in sales, the highest in Company history. The Company recorded over $600 thousand in revenues related to rapid results COVID-19 testing in the last six months of 2020, providing testing to over 5,000 patients. 340B revenue was $2.8 million, representing year-over-year growth of 323% compared to the year ended December 31, 2019.” 

During the third quarter 2020, the Company launched an aggressive expansion of its COVID-19 testing service registered through the FDA under its Emergency Use Authorization (“EUA”) guidelines, featuring Polymerase Chain Reaction (“PCR”) and Antigen testing systems that produces rapid detection of the SARS-CoV-2 virus with market-leading accuracy in 15 to 45 minutes. The systems we use for Rapid Detection of the SARS-CoV-2 virus is a molecular test using a lab technique called PCR, an antigen-based testing system designed to detect proteins from the virus that causes COVID-19. The Company provides these new testing systems to patients at its North Miami Beach location and provides Antigen testing at Palm Springs and Orlando pharmacies. To date, the Company has successfully tested over 5,000 patients and built a reputation as a preferred provider for in-patient and out-patient COVID-19 Rapid Testing solution. 

A significant aspect of RXMD business plan is the development and launching of new and innovative technology solutions to deliver personalized patient-centered care. Recently the Company completed a significant component of that plan through the launch of its ClearMetrX subsidiary, the Company’s first wholly-owned data management company with services designed to support health care organizations across the country. The Company believes in the power of Artificial Intelligence (AI) to improve preventive healthcare by helping physicians make informed decisions in the medication therapy management process. Through ClearMetrX, RXMD has increased its third-party administrative and data management fees to over $700,000 in 2020.  

RXMD CEO is Shital Parikh Mars. According to her linkedin page: Shital Parikh Mars became Chief Executive Officer of Progressive Care in January 2016. Prior to becoming CEO, Ms. Mars was the Chief Operating Officer for 4 years and a vital consultant to Progressive Care from 2010 through 2012. As President and CEO of Spark Financial Consulting, Ms. Mars provided business development consulting services in which she advised the Company on human resources, financial reporting and transactions, operations, compliance, SEC filings, and investor relations, among other things. Prior to her consulting position, Ms. Mars was also the Chief Operating Officer of Basis Financial, a boutique investment banking firm engaged by the Company. Her experience in the financial services industry centers on operational management, preparation and submission of financial statements, mergers & acquisitions, securities offerings, SEC reporting, due diligence, compliance, and regulatory audits. Ms. Mars has a B.S. in Business Administration and Accounting and is a member of the international business honor society, Delta Mu Delta. Ms. Parikh Mars maintains 6 securities license registrations including the Series 7, Series 66, and Series 24. 

On February 21 RXMD announced a transition of its software platform to Newleaf, a best-in-class pharmacy software solution produced by leading pharmacy software and technology provider, Keycentrix (Keycentrix.com). Newleaf is highly adaptable and will provide a viable foundation for the Company’s technology development and deployment objectives, including an expansion in its ClearMetRx business, Progressive Care’s wholly-owned data analytics company, which features services designed to support health care organizations across the country. 

For More on RXMD Subscribe Right Now!

RXMD (Progressive Care) has been making a major move up the charts in recent months from lows well under $0.03 to recent highs of $0.195. RXMD has been under heavy accumulation recently and volume has picked up substantially since a slow December with RXMD regularly trading several million USD per day in dollar volume as a new era of penny stock speculators fueled by robinhood and its 100 million new trading accounts take on the bulletin boards. These are different times than just a few short years ago; now penny stocks such as TSNP can achieve a $6 billion plus market valuation and trade $375 million in dollar volume in a day on the bulletin boards. And TSNP has no stronger fundamentals than RXMD does. Microcapdaily has reported on RXMD incredible rise over the years from Pink Sheets with the yield designation to fully reporting OTCQB with plans to up list to a major exchange. The stock has runner in its blood and a history of big moves, skyrocketing from well under a penny to highs of $0.27 in early 2018. When a penny stock such as RXMD heats up, penny stock speculators pay attention. RXMD just reported a record year in 2020 with more than 530,000 prescriptions filed, the highest in Company history. RXMD did over $40.6 million in sales, the highest in Company history. 340B revenue was $2.8 million, representing year-over-year growth of 323% compared to the year ended December 31, 2019. Recently RXMD has launched an aggressive expansion of its COVID-19 testing service registered through the FDA under its Emergency Use Authorization (“EUA”) guidelines, featuring Polymerase Chain Reaction (“PCR”) and Antigen testing systems that produces rapid detection of the SARS-CoV-2 virus with market-leading accuracy in 15 to 45 minutes. To date, the Company has successfully tested over 5,000 patients and built a reputation as a preferred provider for in-patient and out-patient COVID-19 Rapid Testing solution at its Pharmacy locations in North Miami Beach, Palm Springs and Orlando pharmacies. Since a brief dip Investors are looking for a powerhouse move back to recent highs; a break over $0.195 and its an all-out blue-sky breakout. We will be updating RXMD as events unfold so make sure you are subscribed to Microcapdaily so you know what is going on with RXMD.

Sign Up now for our 100% FREE Penny Stock Newsletter

Disclosure: we hold no position in RXMD either long or short and we have not been compensated for this article.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.